Clival1080
Uploaded on Jan 16, 2026
The biosimilar market is getting bigger, faster, and honestly a little chaotic. Patent cliffs are coming one after another, biologics are losing exclusivity across the world, and every pharma company wants a piece of the action. But even though the opportunity is huge, figuring out where the next biosimilar win really is can feel like trying to read a map in the dark. That’s where drug pipeline intelligence completely changes the game. It helps companies track what’s happening in real time, see which biologics are opening up, understand what competitors are doing, and plan smarter moves. And yes — this is exactly where Clival database fits in. It gives teams the visibility they need without digging through dozens of confusing sources. More Info: https://clival.com/blog/tracking-biosimilar-market-opportunities-using-drug-pipeline-intelligence
Tracking Biosimilar Market Opportunities Using Drug Pipeline Intelligence
Tracking Biosimilar
Market Opportunities
Using Drug Pipeline
Intelligence
INTRODUCTION
The biosimilar market is getting bigger, faster, and honestly a little chaotic. Patent
cliffs are coming one after another, biologics are losing exclusivity across the world,
and every pharma company wants a piece of the action. But even though the
opportunity is huge, figuring out where the next biosimilar win really is can feel like
trying to read a map in the dark.
Why Tracking Biosimilar Opportunities Is So Hard?
On paper, biosimilars sound easy: wait for a biologic to lose its exclusivity, design a
copy, get approval, and sell. But in real life, it’s nowhere near that simple.
Here’s why it gets messy:
•Patent timelines keep changing because of lawsuits, settlements, and extensions.
•Clinical pipelines move fast, with new competitors entering out of nowhere.
•Regulatory data is scattered across multiple agencies and countries.
•Market conditions differ for Europe, the U.S., India, LATAM, and Southeast Asia.
How Drug Pipeline Intelligence Helps Spot Biosimilar Market
Opportunities?
1. Tracking LOE and Patent Expiries (The Real Starting Point)
2. Understanding the Competitive Landscape Before You Jump In
3. Monitoring Global Regulatory Filings and Approvals
4. Evaluating Scientific and Technological Requirements
5. Mapping API and CDMO Availability (A Step Most People Forget)
How Companies Use Market Intelligence to Make Better
Biosimilar Decisions?
1. Identify biologics losing exclusivity soon
2. Score each molecule based on market size, unmet need, and competitive intensity
3. Check pipeline saturation using developer-level analytics
4. Scan regulatory landscapes to find the easiest markets
5. Evaluate scientific and technical requirements
6. Identify capable CDMOs and suppliers
7. Build a go/no-go strategy
8. Track updates continuously with alerts
Conclusion
The biosimilar landscape is expanding fast, but so is the competition. Companies
that rely on slow updates or outdated data will always be a step behind. But those
who use drug pipeline intelligence can spot opportunities early, avoid market
saturation, reduce development risk, and plan smarter launches.
WEBSITE :
WWW.CLIVAL.COM
• WWW.LIFESCIENCEINTELLIPEDIA.COM
• WWW.CHEMXPERT.COM
LOCATION:- C-89, SECTOR-65 NOIDA-U.P. 201301
(INDIA)
E-MAIL:- [email protected] |
[email protected]
PHONE:- +91-120-6631301-335
MOB NO:- +91-9990237670
THANK
YOU!
Comments